Literature DB >> 10781864

Development of a multi-specificity opsonophagocytic killing assay.

M H Nahm1, D E Briles, X Yu.   

Abstract

The opsonophagocytic-killing assay (OPKA) is one of the primary surrogate assays for evaluating the pneumococcal capsular polysaccharide-protein conjugates under development as vaccines. Because each vaccine contains seven or more different conjugates, multiple OPKA must be performed on each serum. Moreover, the large number of assays can deplete serum samples from infants. To reduce the amount of serum and effort required to conduct OPKA we developed a multi-specificity OPKA using antibiotic resistant pneumococci. Equal numbers of optochin-resistant serotype 6B and streptomycin-resistant 19F pneumococci were used as the target bacteria. Surviving bacteria of each serotype were enumerated by plating on agar containing the appropriate antibiotic. In an examination of 25 immune sera the results obtained with this new assay correlated well with those obtained when bacterial targets were examined individually. By using additional antibiotic resistance markers, more than two specificities can be examined in a single assay.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10781864     DOI: 10.1016/s0264-410x(00)00044-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  Chromogenic assay measuring opsonophagocytic killing capacities of antipneumococcal antisera.

Authors:  J S Lin; M K Park; M H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

Review 2.  Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies.

Authors:  R A Fleck; S Romero-Steiner; M H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

3.  Evaluation of multiplex flow cytometric opsonophagocytic assays for determination of functional anticapsular antibodies to Streptococcus pneumoniae.

Authors:  Joseph E Martinez; Elizabeth A Clutterbuck; Han Li; Sandra Romero-Steiner; George M Carlone
Journal:  Clin Vaccine Immunol       Date:  2006-04

Review 4.  Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines.

Authors:  Sandra Romero-Steiner; Carl E Frasch; George Carlone; Roland A Fleck; David Goldblatt; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2006-02

Review 5.  Measuring immune responses to pneumococcal vaccines.

Authors:  David C LaFon; Moon H Nahm
Journal:  J Immunol Methods       Date:  2018-08-08       Impact factor: 2.303

6.  Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies.

Authors:  Robert L Burton; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2006-09

7.  Peripheral CD4 T follicular cells induced by a conjugated pneumococcal vaccine correlate with enhanced opsonophagocytic antibody responses in younger individuals.

Authors:  Sarah Sterrett; Binghao J Peng; Robert L Burton; David C LaFon; Andrew O Westfall; Suddham Singh; Michael Pride; Annaliesa S Anderson; Gregory C Ippolito; Harry W Schroeder; Moon H Nahm; A Krishna Prasad; Paul Goepfert; Anju Bansal
Journal:  Vaccine       Date:  2020-01-03       Impact factor: 3.641

8.  Development of a multiplexed opsonophagocytic killing assay (MOPA) for group B Streptococcus.

Authors:  Min Joo Choi; Ji Yun Noh; Hee Jin Cheong; Woo Joo Kim; Shun-Mei Lin; Yong Zhi; Jae Hyang Lim; Sangyong Lim; Ho Seong Seo; Joon Young Song
Journal:  Hum Vaccin Immunother       Date:  2017-10-30       Impact factor: 3.452

9.  Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies.

Authors:  Kyung Hyo Kim; Jigui Yu; Moon H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

10.  Correlation of pneumococcal antibody concentration and avidity with patient clinical and immunologic characteristics.

Authors:  Ari J Fried; Michelle L Altrich; Hongye Liu; John F Halsey; Francisco A Bonilla
Journal:  J Clin Immunol       Date:  2013-02-03       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.